EXPERIENCE OF THE SUCCESSFUL CANAKINUMAB TREATMENT OF A PATIENT WITH UNDIFFERENTIATED AUTOINFLAMMATORY SYNDROME
https://doi.org/10.15690/vsp.v15i5.1627
Abstract
The article presents a case of a successful canakinumab application (preparation of monoclonal antibodies to 1 interleukin) for undifferentiated autoinflammatory syndrome in a patient with refractoriness to oral glucocorticosteroids and genetically engineered biological drugs with a different action mechanisms. After 8 weeks of canakinumab therapy, systemic manifestations were cropped, and laboratory parameters of the disease activity were normalized. During the entire care period (12 months), neither serious adverse events nor increased incidence of acute respiratory infections have been reported.
About the Authors
Tatyana V. Sleptsova
Scientific Center of Children’s Health
Russian Federation
Russian Federation
Еkaterina I. Alexeeva
Scientific Center of Children’s Health; Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Тatyana М. Bzarova
Scientific Center of Children’s Health; Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Kirill V. Savostyanov
Scientific Center of Children’s Health
Russian Federation
Russian Federation
Аlexander A. Pushkov
Scientific Center of Children’s Health
Russian Federation
Russian Federation
Kseniya B. Isaeva
Scientific Center of Children’s Health
Russian Federation
Russian Federation
Rina V. Denisova
Scientific Center of Children’s Health
Russian Federation
Russian Federation
Оlga L. Lomakina
Scientific Center of Children’s Health
Russian Federation
Russian Federation
References
1. Гатторно М. Аутовоспалительные заболевания у детей // Вопросы современной педиатрии. — 2014. — Т. 13. — № 2. — С. 55–64. [Gattorno M. Autoinflammatory diseases in children (The Lecture from 18th of September 2013, Conference «Topical Problems of Diagnostics and Treatment of Juvenile Rheumatoid Arthritis» (18–20 of September, 2013, St. Petersburg)). Current pediatrics. 2014,13(2):55–64. (In Russ).] doi: 10.15690/vsp.v13i2.973.
2. Barron K, Kastner D. Periodic fever syndromes and other inherited autoinflammatory diseases. In: Textbook of pediatric rheumatology. Ed by R.E. Petty. 7th ed. Philadelphia: Saunders Elsevier, 2015. p. 609–626.
3. Caso F, Rigante D, Vitale A, et al. Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol. 2013,2013:513782. doi: 10.1155/2013/513782.
4. Galon J, Aksentijevich I, McDermott MF, et al. TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol. 2000,12(4):479–486. doi: 10.1016/s0952-7915(00)00124-2.
5. Takei S. Systemic JIA as an autoinflammatory disease. Inflamm Regen. 2011,31(1):52–62. doi: 10.2492/inflammregen.31.52.
6. Harrison SR, McGonagle D, Nizam S, et al. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. JCI . 2016,1(6):e86336. doi: 10.1172/jci.insight.86336.
7. Caorsi R, Federici S, Gattorno M. Biologic drugs in auto-inflammatory syndromes. Autoimmun Rev. 2012,12(1):81–86. doi: 10.1016/j.autrev.2012.07.027.
8. Federici S, Martini A, Gattorno M. The central role of Anti-IL-1 blockade in the treatment of monogenic and multi-factorial autoinflammatory diseases. Front Immunol. 2013,4:351. doi: 10.3389/fimmu.2013.00351.
9. Lachmann H, Kone-Paut I, Kuemmerle-Deschner GB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009,360(23):2416–2425. doi: 10.1056/nejmoa0810787.
10. Kuemmerle-Deschner JB, Hachulla E, Cartwright R, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011,70(12):2095–2102. doi: 10.1136/ard.2011.152728.
11. Алексеева Е.И., Савостьянов К.В., Слепцова Т.В. и др. Клинические и молекулярно-генетические особенности аутовоспалительных синдромов у детей // Вопросы современной педиатрии. — 2015. — Т. 14. — № 3. — С. 358–363. [Alexeeva ЕI, Savostyanov KV, Sleptsova ТV, et al. Clinical and molecular genetic features of autoinflammatory syndromes in children. Current pediatrics. 2015,14(3):358–363. (In Russ).] doi: 10.15690/vsp.v14i3.1372.
Review
For citations:
Sleptsova T.V., Alexeeva Е.I., Bzarova Т.М., Savostyanov K.V., Pushkov А.A., Isaeva K.B., Denisova R.V., Lomakina О.L. EXPERIENCE OF THE SUCCESSFUL CANAKINUMAB TREATMENT OF A PATIENT WITH UNDIFFERENTIATED AUTOINFLAMMATORY SYNDROME. Current Pediatrics. 2016;15(5):522-526. (In Russ.) https://doi.org/10.15690/vsp.v15i5.1627
Views:
926
Email this article 
